SCHEMBL5645876

SCHEMBL5645876

Cc1ccc(/C=C/S(=O)(=O)O)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
MAPT P10636 10/20 0.44
RAB9A P51151 8/20 0.44
SMN1; SMN2 Q16637 7/20 0.44
NPC1 O15118 6/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
KMT2A Q03164 9/20 0.42
ALDH1A1 P00352 7/20 0.42
HPGD P15428 4/20 0.42
TDP1 Q9NUW8 3/20 0.42
RECQL P46063 2/20 0.42
THRB P10828 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 5/20 0.41
KDM4E B2RXH2 3/20 0.41
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5645747 1.00 PTGS1 (0.50) PTGS1PTGS2MAPTRAB9ASMN1; SMN2
SCHEMBL5646036 0.81 PTGS1 (0.46) PTGS1PTGS2MAPTRAB9ASMN1; SMN2
SCHEMBL5646039 0.81 PTGS1 (0.46) PTGS1PTGS2MAPTRAB9ASMN1; SMN2
SCHEMBL4256006 0.79 ALDH1A1 (0.40) PTGS1PTGS2MAPTRAB9ASMN1; SMN2
SCHEMBL4627757 0.77 PTGS1 (0.47) PTGS1PTGS2MAPTRAB9AKMT2A
SCHEMBL4659487 0.77 CA12 (0.42) MAPTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL4627759 0.77 PTGS1 (0.47) PTGS1PTGS2MAPTRAB9AKMT2A
SCHEMBL4659478 0.77 CA12 (0.42) MAPTRAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL13226178 0.76 MAPT (0.61) PTGS1PTGS2MAPTRAB9ASMN1; SMN2
SCHEMBL14433026 0.74 PTGS1 (0.59) PTGS1PTGS2MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166586-B2 Sulfonamide lactam inhibitors of FXa and method BRISTOL MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
US-20040186134-A1 Sulfonamide lactam inhibitors of FXa and method O'CONNOR STEPHEN P (US) 2004-09-23 US disclosed
EP-1358178-A2 SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA Bristol-Myers Squibb Company (US) 2003-11-05 EP disclosed
US-6555542-B1 Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis BRISTOL-MYERS SQUIBB COMPANY 2003-04-29 US disclosed
WO-2002060894-A2 SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186134-A1 Sulfonamide lactam inhibitors of FXa and method STS, SULT1E1, F8 PTGS1 1315/4885PTGS2 2022/4885MAPT 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.